A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma

被引:0
作者
A J Davies
A M Lee
C Taylor
A J Clear
L K Goff
S Iqbal
D Cuthbert-Heavens
M Calaminici
A J Norton
T A Lister
J Fitzgibbon
机构
[1] Cancer Research UK Medical Oncology Unit,Department of Histopathology
[2] Bart's and The Royal London School of Medicine and Dentistry,undefined
[3] Cancer Research UK Mutation Detection Facility,undefined
[4] St James's Hospital,undefined
[5] St Bartholomew's Hospital,undefined
来源
Leukemia | 2005年 / 19卷
关键词
immunohistochemistry; MDM2; mutation detection; follicular lymphoma;
D O I
暂无
中图分类号
学科分类号
摘要
The role of TP53 mutation in transformation of follicular lymphoma (FL) to diffuse large B-cell lymphoma (t-FL) was examined in a panel of 91 lymph node biopsies derived from 29 patients pre- and post-transformation. The entire TP53 coding sequence was screened and immunocytochemistry performed to determine expression of p53 and its key regulator MDM2. A total of 10 mutations were detected in eight patients (28%), although none were present at FL diagnosis. Mutations were not detected solely at the time of transformation; in three patients, mutated TP53 arose in at least one antecedent FL sample (6 months, 2.5 years and 4 years prior to transformation). Loss of heterozygosity at the TP53 locus occurred in 2/20 informative patients (only in t-FL samples). p53 staining was positive in 82% (9/11) of available biopsies with a missense mutation, and negative in 71% (45/63) with wtTP53. MDM2 expression was significantly higher in t-FL samples (mean 72% positive; 95% confidence interval (95% CI) 68–76%) than FL (mean 58% positive; 95% CI 54–62%) (P<0.001) but did not correlate with TP53 status. TP53 mutation has only a limited role in the transformation of FL, exerting a heterogeneous influence upon phenotypic change. In contrast, dysregulation of MDM2 is frequent and may provide a more rational therapeutic target.
引用
收藏
页码:1459 / 1465
页数:6
相关论文
共 259 条
[1]  
Gallagher CJ(1986)Follicular lymphoma: prognostic factors for response and survival J Clin Oncol 4 1470-1480
[2]  
Gregory WM(1993)Natural history of and therapy for the indolent non-Hodgkin's lymphomas Semin Oncol 20 75-88
[3]  
Jones AE(1979)Histological transformation of non-Hodgkin's lymphoma: a prospective study Cancer 44 645-651
[4]  
Stansfeld AG(1982)Histologic progression in non-Hodgkin's lymphoma Blood 59 258-264
[5]  
Richards MA(1983)Histologic conversion in the non-Hodgkin's lymphomas J Clin Oncol 1 11-16
[6]  
Dhaliwal HS(1997)Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients J Clin Oncol 15 1587-1594
[7]  
Horning SJ(1983)An autopsy study of histologic progression in non-Hodgkin's lymphomas 192 cases from the National Cancer Institute Cancer 52 393-398
[8]  
Cullen MH(1998)High-dose therapy with autologous haematopoietic support in patients with transformed follicular lymphoma: a study of 27 patients from a single centre Ann Oncol 9 865-869
[9]  
Lister TA(2001)Autotransplants for histologically transformed follicular non-Hodgkin's lymphoma Br J Haematol 113 202-208
[10]  
Brearley RI(2001)Copy number gain at 12q12–14 may be important in the transformation from follicular lymphoma to diffuse large B cell lymphoma Br J Cancer 84 499-503